Rezolute rises after FDA talks on rare low blood sugar disease drug

Shares of biotech firm Rezolute RZLT.O rise 7% to $2.57

Co says it met the FDA to discuss next steps for its experimental drug ersodetug for congenital hyperinsulinism, a rare condition that causes dangerously low blood sugar in children

Says late‑stage trial showed the drug reduced low blood sugar episodes from baseline, but did not beat placebo on its main goal

Says trial results were affected by patient behavior, as families may have changed how closely blood sugar was monitored

Adds FDA acknowledged challenges of trials in this disease and said it will review full data before deciding on approval filing or additional studies

Early data from an ongoing extension study showed continued benefits - RZLT

RZLT fell ~52% in 2025